BWM
VIRX

BCS Wealth Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BCS Wealth Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,382
Closed -$22K – 133
2020
Q2 		$22K Hold
2,382
– – 0.01% 123
2020
Q1 		$35K Hold
2,382
– – 0.02% 105
2019
Q4 		$28K Buy
+2,382
New +$39.9K 0.02% 113

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BCS Wealth Management's VIRX Position: Q3 2020 in Review

BCS Wealth Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2020, closing a stake of 2,382 shares — an estimated $22K sold.

BCS Wealth Management first reported a position in VIRX in Q4 2019 and held it in 3 quarters. The position peaked at $35K in Q1 2020. 28 funds tracked by Wall St. Rank hold VIRX as of Q3 2020.

  • BCS Wealth Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • BCS Wealth Management sold 2,382 Viracta Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $22K.
  • BCS Wealth Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • BCS Wealth Management's Viracta Therapeutics, Inc. Common Stock position peaked at $35K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2020.

Based on BCS Wealth Management's 13F filing for Q3 2020, filed 23 Oct 2020.